First guide for managing bleeding with NOACs
Recommendations include when to use reversal agents
11th December 2017
The clinical problem of managing acute bleeding in patients taking anticoagulants is addressed in a new guidance by US cardiology experts.

The evidence-based guidelines pertain to both non-vitamin K oral anticoagulants (NOACs), such as dabigatran, apixaban and rivaroxaban, and vitamin K antagonists (VKAs), such as warfarin.
The decision pathway considers the severity of the bleed (major vs non-major), the need for reversal, and the appropriateness and time of restarting anticoagulation.
Here are some of the main recommendations for controlling a major